NUT carcinoma

Last updated
NUT carcinoma (NC)
Other namesNUT midline carcinoma (NMC) [1]
NUT midline carcinoma - very high mag.jpg
Micrograph of a NUT carcinoma with the characteristic well-differentiated islands of squamous epithelium. H&E stain.
Specialty Oncology

NUT carcinoma (NC; formerly NUT midline carcinoma (NMC)) is a rare genetically defined, very aggressive squamous cell epithelial cancer that usually arises in the midline of the body and is characterized by a chromosomal rearrangement in the nuclear protein in testis gene (i.e. NUTM1 gene). [2] In approximately 75% of cases, the coding sequence of NUTM1 in band 14 on the long (or "q") arm of chromosome 15 is fused to BRD4 or BRD3 , which creates a chimeric gene that encodes the BRD-NUT fusion protein. The remaining cases, the fusion of NUTM1 is to an unknown partner gene, usually called NUT-variant.

Contents

The name NUT carcinoma was introduced as the carcinoma does not only occur in the body midline; therefore, WHO also changed the name in 2015 in the WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. [3]

Signs and symptoms

The number of cases per year is likely grossly underestimated. One study suggests the incidence rate is likely around 1,000 cases per year in the United States. [4] The symptoms are similar to other forms of cancer and dependent on the stage. While generalized symptoms (weight loss and fatigue) may be seen, site specific symptoms are also present. If the tumor involves the head and neck region (in about 35%), then pain, a mass, obstructive symptoms, among others, may be experienced. NUT carcinomas are not specific to any tissue type or organ. [5] Common sites include the head, neck and mediastinum. [6] The median age at diagnosis is 16–23 years, but older patients may be affected. [7] [8]

Diagnosis

NC when viewed microscopically, are poorly differentiated carcinomas which show abrupt transitions to islands of well-differentiated squamous epithelium. [5] [6] This tumor pattern is not specific or unique to NUT carcinoma, but this pattern is most suggestive of the diagnosis. The neoplastic cells will show a positive reaction with various cytokeratins, p63, CEA, and CD34 immunohistochemistry.

However, the defining feature of NCs is rearrangement of the NUT gene. [5] Most common is a translocation involving the BRD4 gene and NUT gene (t(15;19)(q13;p13.1)). [6] [9] Therefore, staining with the NUT antibody confirms the diagnosis (although only available in a limited number of laboratories). [10]

Differential diagnosis

The differential diagnosis is quite wide, but it is important to consider this tumor type when seeing a poorly differentiated tumor that shows abrupt areas of keratinization. Other tumors included in the differential diagnosis are sinonasal undifferentiated carcinomas, Ewing sarcoma/Primitive neuroectodermal tumor, leukemia, rhabdomyosarcoma, and melanoma. When NUT midline carcinoma is seen in the head and neck, the squamous lining of the cavities may be entrapped by the neoplastic cells, and so it is important to document the carcinoma cells in the rest of the tumor by a variety of stains (including cytokeratin or p63). One of the most helpful and characteristic findings is the focal abrupt squamous differentiation, where stratification and gradual differentiation are absent, resembling a Hassall corpuscle of the thymus. [11]

Treatment

Currently, the standard treatment approach is a multimodal approach involving surgery as well as radio-chemotherapy. As the mean survival under this treatment regimen is only 5–7 months, [12] [7] more specific treatment options are under investigation: Specific molecular targeted therapies (including BET inhibitors and histone deacetylase inhibitors (HDACi)) may help to yield growth arrest of the neoplastic cells. [11] Two genetically engineered mouse models (GEMMs) of NC have been reported by the French lab (2023 [13] ) and Gu lab (2024 [14] ). These models demonstrate that BRD4-NUT alone drives malignant transformation and spread of NUT carcinoma and will help enable the discovery and development of novel, targeted therapies for NC.

Prognosis

NUT carcinoma is very resistant to standard chemotherapy treatments. The tumor may initially respond to therapy, and then rapid recurrence is experienced. A multimodality approach to treatment is advocated, especially since most patients present with advanced disease. Treatment must be tailored to the individual patient, with several promising new targeted molecular therapies in clinical trials. [15] Overall, there is a mean survival of 6–9 months. [16] [17]

See also

Related Research Articles

<span class="mw-page-title-main">Adenoid cystic carcinoma</span> Rare Form of Cancer

Adenoid cystic carcinoma is a rare type of cancer that can exist in many different body sites. This tumor most often occurs in the salivary glands, but it can also be found in many anatomic sites, including the breast, lacrimal gland, lung, brain, Bartholin gland, trachea, and the paranasal sinuses.

<span class="mw-page-title-main">Carcinoembryonic antigen</span> Glycoprotein secreted into the luminal surface of the epithelia in the gastrointestinal tract

Carcinoembryonic antigen (CEA) describes a set of highly-related glycoproteins involved in cell adhesion. CEA is normally produced in gastrointestinal tissue during fetal development, but the production stops before birth. Consequently, CEA is usually present at very low levels in the blood of healthy adults. However, the serum levels are raised in some types of cancer, which means that it can be used as a tumor marker in clinical tests. Serum levels can also be elevated in heavy smokers.

<span class="mw-page-title-main">Blastoma</span> Type of cancer arising from precursor cells

A blastoma is a type of cancer, more common in children, that is caused by malignancies in precursor cells, often called blasts. Examples are nephroblastoma, medulloblastoma, and retinoblastoma. The suffix -blastoma is used to imply a tumor of primitive, incompletely differentiated cells, e.g., chondroblastoma is composed of cells resembling the precursor of chondrocytes.

<span class="mw-page-title-main">Verrucous carcinoma</span> Medical condition

Verrucous carcinoma (VC) is an uncommon variant of squamous cell carcinoma. This form of cancer is often seen in those who chew tobacco or use snuff orally, so much so that it is sometimes referred to as "Snuff dipper's cancer".

<span class="mw-page-title-main">Undifferentiated pleomorphic sarcoma</span> Medical condition

Undifferentiated pleomorphic sarcoma (UPS), also termed pleomorphic myofibrosarcoma, high-grade myofibroblastic sarcoma, and high-grade myofibrosarcoma, is characterized by the World Health Organization (WHO) as a rare, poorly differentiated neoplasm. WHO classified it as one of the undifferentiated/unclassified sarcomas in the category of tumors of uncertain differentiation. Sarcomas are cancers derived mesenchymal stem cells that typically develop in bone, muscle, fat, blood vessels, lymphatic vessels, tendons, and ligaments. More than 70 sarcoma subtypes have been described. The UPS subtype of these sarcomas consists of tumor cells that are poorly differentiated and may appear as spindle-shaped cells, histiocytes, and giant cells. UPS is considered a diagnosis that defies formal sub-classification after thorough histologic, immunohistochemical, and ultrastructural examinations fail to identify the type of cells involved.

<span class="mw-page-title-main">Non-small-cell lung cancer</span> Any type of epithelial lung cancer other than small-cell lung carcinoma

Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both preoperatively and postoperatively.

<span class="mw-page-title-main">Sebaceous carcinoma</span> Malignant tumor of oil glands in the skin

Sebaceous carcinoma, also known as sebaceous gland carcinoma (SGc), sebaceous cell carcinoma, and meibomian gland carcinoma, is an uncommon malignant cutaneous (skin) tumor. Most are typically about 1.4 cm at presentation. SGc originates from sebaceous glands in the skin and, therefore, may originate anywhere in the body where these glands are found. SGc can be divided into 2 types: periocular and extraocular. The periocular region is rich in sebaceous glands making it a common site of origin. The cause of these lesions in the vast majority of cases is unknown. Occasional cases may be associated with Muir-Torre syndrome. SGc accounts for approximately 0.7% of all skin cancers, and the incidence of SGc is highest in Caucasian, Asian, and Indian populations. Due to the rarity of this tumor and variability in clinical and histological presentation, SGc is often misdiagnosed as an inflammatory condition or a more common neoplasm. SGc is commonly treated with wide local excision or Mohs micrographic surgery, and the relative survival rates at 5 and 10 years are 92.72 and 86.98%, respectively.

<span class="mw-page-title-main">Desmoplasia</span> Growth of fibrous or connective tissue

In medicine, desmoplasia is the growth of fibrous connective tissue. It is also called a desmoplastic reaction to emphasize that it is secondary to an insult. Desmoplasia may occur around a neoplasm, causing dense fibrosis around the tumor, or scar tissue (adhesions) within the abdomen after abdominal surgery.

<span class="mw-page-title-main">Poroma</span>

Poromas are rare, benign, cutaneous adnexal tumors. Cutaneous adnexal tumors are a group of skin tumors consisting of tissues that have differentiated towards one or more of the four primary adnexal structures found in normal skin: hair follicles, sebaceous sweat glands, apocrine sweat glands, and eccrine sweat glands. Poromas are eccrine or apocrine sweat gland tumors derived from the cells in the terminal portion of these glands' ducts. This part of the sweat gland duct is termed the acrosyringium and had led to grouping poromas in the acrospiroma class of skin tumors. Here, poromas are regarded as distinct sweat gland tumors that differ from other sweat gland tumors by their characteristic clinical presentations, microscopic histopathology, and the genetic mutations that their neoplastic cells have recently been found to carry.

Porocarcinoma (PCA) is a rare form of skin cancer that develops in eccrine sweat glands, i.e. the body's widely distributed major type of sweat glands, as opposed to the apocrine sweat glands which are located primarily in the armpits and perineal area. This cancer typically develops in individuals as a single cutaneous tumor in the intraepidermal spiral part of these sweat glands' ducts at or near to where they open on the skin's surface. PCA tumors are classified as one form of the cutaneous adnexal tumors; in a study of 2,205 cases, PCA was the most common (11.8%) form of these tumors.

Large cell lung carcinoma with rhabdoid phenotype (LCLC-RP) is a rare histological form of lung cancer, currently classified as a variant of large cell lung carcinoma (LCLC). In order for a LCLC to be subclassified as the rhabdoid phenotype variant, at least 10% of the malignant tumor cells must contain distinctive structures composed of tangled intermediate filaments that displace the cell nucleus outward toward the cell membrane. The whorled eosinophilic inclusions in LCLC-RP cells give it a microscopic resemblance to malignant cells found in rhabdomyosarcoma (RMS), a rare neoplasm arising from transformed skeletal muscle. Despite their microscopic similarities, LCLC-RP is not associated with rhabdomyosarcoma.

Targeted therapy of lung cancer refers to using agents specifically designed to selectively target molecular pathways responsible for, or that substantially drive, the malignant phenotype of lung cancer cells, and as a consequence of this (relative) selectivity, cause fewer toxic effects on normal cells.

<span class="mw-page-title-main">ALK positive lung cancer</span> Medical condition

ALK positive lung cancer is a primary malignant lung tumor whose cells contain a characteristic abnormal configuration of DNA wherein, most frequently, the echinoderm microtubule-associated protein-like 4 (EML4) gene is fused to the anaplastic lymphoma kinase (ALK) gene. Less frequently, there will be novel translocation partners for the ALK gene, in place of EML4. This abnormal gene fusion leads to the production of a protein that appears, in many cases, to promote and maintain the malignant behavior of the cancer cells.

In molecular biology mir-708 microRNA is a short RNA molecule. MicroRNAs function to regulate the expression levels of other genes by several mechanisms. miR-708 is located on chromosome 11q14.1 and is endcoded in intron 1 of the ODZ4 gene. It is most highly expressed in the brain and eyes, and has a supposed role in endoplasmic reticular stress of the eye.

<span class="mw-page-title-main">JQ1</span> Chemical compound

JQ1 is a thienotriazolodiazepine and a potent inhibitor of the BET family of bromodomain proteins which include BRD2, BRD3, BRD4, and the testis-specific protein BRDT in mammals. BET inhibitors structurally similar to JQ1 are being tested in clinical trials for a variety of cancers including NUT midline carcinoma. It was developed by the James Bradner laboratory at Brigham and Women's Hospital and named after chemist Jun Qi. The chemical structure was inspired by patent of similar BET inhibitors by Mitsubishi Tanabe Pharma. Structurally it is related to benzodiazepines. While widely used in laboratory applications, JQ1 is not itself being used in human clinical trials because it has a short half life.

<span class="mw-page-title-main">Squamous-cell carcinoma of the lung</span> Medical condition

Squamous-cell carcinoma (SCC) of the lung is a histologic type of non-small-cell lung carcinoma (NSCLC). It is the second most prevalent type of lung cancer after lung adenocarcinoma and it originates in the bronchi. Its tumor cells are characterized by a squamous appearance, similar to the one observed in epidermal cells. Squamous-cell carcinoma of the lung is strongly associated with tobacco smoking, more than any other forms of NSCLC.

<span class="mw-page-title-main">Squamous-cell carcinoma</span> Carcinoma that derives from squamous epithelial cells

Squamous-cell carcinoma (SCC), also known as epidermoid carcinoma, comprises a number of different types of cancer that begin in squamous cells. These cells form on the surface of the skin, on the lining of hollow organs in the body, and on the lining of the respiratory and digestive tracts.

<span class="mw-page-title-main">Histopathology of colorectal adenocarcinoma</span> Analysis of tissue to identify colorectal cancer characteristics

The histopathology of colorectal cancer of the adenocarcinoma type involves analysis of tissue taken from a biopsy or surgery. A pathology report contains a description of the microscopical characteristics of the tumor tissue, including both tumor cells and how the tumor invades into healthy tissues and finally if the tumor appears to be completely removed. The most common form of colon cancer is adenocarcinoma, constituting between 95% and 98% of all cases of colorectal cancer. Other, rarer types include lymphoma, adenosquamous and squamous cell carcinoma. Some subtypes have been found to be more aggressive.

The nuclear protein in testis gene encodes a 1,132-amino acid protein termed NUT that is expressed almost exclusively in the testes, ovaries, and ciliary ganglion. NUT protein facilitates the acetylation of chromatin by histone acetyltransferase EP300 in testicular spermatids. This acetylation is a form of chromatin remodeling which compacts spermatid chromatin, a critical step required for the normal conduct of spermatogenesis, i.e. the maturation of spermatids into sperm. Male mice that lacked the mouse Nutm1 gene using a gene knockout method had abnormally small testes, lacked sperm in their cauda epididymis, and were completely sterile. These findings indicate that Nutm1 gene is essential for the development of normal fertility in male mice and suggest that the NUTM1 gene may play a similar role in men.

Papillary carcinomas of the breast (PCB), also termed malignant papillary carcinomas of the breast, are rare forms of the breast cancers. The World Health Organization (2019) classified papillary neoplasms of the breast into 5 types: intraductal papilloma, papillary ductal carcinoma in situ (PDCIS), encapsulated papillary carcinoma (EPC), solid-papillary carcinoma (SPC), and invasive papillary carcinoma (IPC). The latter four carcinomas are considered here; intraductal papilloma is a benign neoplasm. The World Health Organization regarded solid papillary carcinoma as having two subtypes: in situ and invasive SPC.

References

  1. ↑ RESERVED, INSERM US14-- ALL RIGHTS. "Orphanet: NUT midline carcinoma". www.orpha.net. Retrieved 18 November 2019.{{cite web}}: CS1 maint: numeric names: authors list (link)
  2. ↑ Online Mendelian Inheritance in Man (OMIM): 608963
  3. ↑ International Agency for Research on Cancer (2015). WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. William D. Travis, Elisabeth Brambilla, Allen Burke, Alexander Marx, Andrew G. Nicholson (4th ed.). Lyon. ISBN   978-92-832-2436-5. OCLC   898924651.{{cite book}}: CS1 maint: location missing publisher (link)
  4. ↑ Stevens, Todd M; Morlote, Diana; Xiu, Joanne; Swensen, Jeffrey; Weber-Brandwein, Margaret; Miettinen, Markku M; Gatalica, Zoran; Bridge, Julia A (Feb 2019). "NUTM1-rearranged neoplasia: a multi-institution experience yields novel fusion partners and expands the histologic spectrum". Modern Pathology. 32 (6): 764–773. doi:10.1038/s41379-019-0206-z. PMC   8194366 . PMID   30723300.
  5. 1 2 3 French, CA. (Nov 2010). "NUT midline carcinoma". Cancer Genet Cytogenet. 203 (1): 16–20. doi:10.1016/j.cancergencyto.2010.06.007. PMC   3000636 . PMID   20951314.
  6. 1 2 3 French, CA. (Jun 2010). "Demystified molecular pathology of NUT midline carcinomas". J Clin Pathol. 63 (6): 492–6. doi:10.1136/jcp.2007.052902. PMID   18552174. S2CID   2200842.
  7. 1 2 Giridhar, Prashanth; Mallick, Supriya; Kashyap, Lakhan; Rath, Goura Kishor (2018-01-22). "Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases". European Archives of Oto-Rhino-Laryngology. 275 (3): 815–821. doi:10.1007/s00405-018-4882-y. ISSN   0937-4477. PMID   29356890. S2CID   3379707.
  8. ↑ Bauer, Daniel E; Mitchell, Chelsey M; Strait, Kelly M; Lathan, Christopher S; Stelow, Edward B; Lüer, Sonja C; Muhammed, Somala; Evans, Andrew G; Sholl, Lynette M; Rosai, Juan; Giraldi, Eugenia; Oakley, Richard P; Rodriguez-Galindo, Carlos; London, Wendy B; Sallan, Stephen E; Bradner, James E; French, Christopher A (Oct 2012). "Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma". Clinical Cancer Research. 18 (20): 5773–5779. doi:10.1158/1078-0432.CCR-12-1153. PMC   3473162 .
  9. ↑ Online Mendelian Inheritance in Man (OMIM): 608749
  10. ↑ French, Christopher A. (2018-10-26). "NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment". Pathology International. 68 (11): 583–595. doi: 10.1111/pin.12727 . ISSN   1320-5463. PMID   30362654. S2CID   53104234.
  11. 1 2 French, C. A. (2013). "The importance of diagnosing NUT midline carcinoma". Head and Neck Pathology. 7 (1): 11–6. doi:10.1007/s12105-013-0428-1. PMC   3597165 . PMID   23463074.
  12. ↑ Bauer, Daniel E.; Mitchell, Chelsey M.; Strait, Kelly M.; Lathan, Christopher S.; Stelow, Edward B.; Lüer, Sonja C.; Muhammed, Somala; Evans, Andrew G.; Sholl, Lynette M.; Rosai, Juan; Giraldi, Eugenia (2012-08-15). "Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma". Clinical Cancer Research. 18 (20): 5773–5779. doi:10.1158/1078-0432.ccr-12-1153. ISSN   1078-0432. PMC   3473162 . PMID   22896655.
  13. ↑ Durall, R Taylor; Huang, Julianna; Wojenski, Luke; Huang, Yeying; Gokhale, Prafulla C; Leeper, Brittaney A; Nash, Joshua O; Ballester, Pedro L; Davidson, Scott; Shlien, Adam; Sotirakis, Emmanuel; Bertaux, Fabien; Dubus, Vincent; Luo, Jia; Wu, Catherine J; Keskin, Derin B; Eagen, Kyle P; Shapiro, Geoffrey I; French, Christopher A (Dec 2023). "The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma". Cancer Research. 83 (23): 3846–3860. doi:10.1158/0008-5472.CAN-23-2545. PMC   10690098 .
  14. ↑ Zheng, Dejin; Elnegiry, Ahmed A; Luo, Chenxiang; Bendahou, Mohammed Amine; Xie, Liangqi; Bell, Diana; Takahashi, Yoko; Hanna, Ehab; Mias, George I; Tsoi, Mayra F; Gu, Bin (May 2024). "Brd4::Nutm1 fusion gene initiates NUT carcinoma in vivo". Life Science Alliance. 7 (7). doi: 10.26508/lsa.202402602 . PMC   11082452 .
  15. ↑ "NUT Carcinoma Registry - Clinical Trials".
  16. ↑ NEJM 367:647 doi : 10.1056/NEJMra1112635
  17. ↑ "NUT Carcinoma Registry - Basic Facts About NUT Carcinoma".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.